SynthesisHIV clinical trials
A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.
Synthesis in HIV clinical trials. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity.American journal of physiology. Endocrinology and metabolism · 2011Trial
- Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy.HIV clinical trialsTrial
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.Frontiers in endocrinology · 2022Article
- Peroxisome Proliferator-Activated Receptor-gamma agonists exhibit anti-inflammatory and antiviral effects in an EcoHIV mouse model.Scientific reports · 2019Article
- Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.Drugs · 2016Review
- Lipodystrophic diabetes mellitus: a lesson for other forms of diabetes?Current diabetes reports · 2015Review
- HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.Journal of the International AIDS Society · 2015Review
- The synergistic effects of HIV, diabetes, and aging on cognition: implications for practice and research.The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses · 2014Review
- Biochemical Manifestation of HIV Lipodystrophy Syndrome.International journal of MCH and AIDS · 2012Review
- Management of the metabolic effects of HIV and HIV drugs.Nature reviews. Endocrinology · 2011Review
- Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment.Metabolism: clinical and experimental · 2011Article
- Lipodystrophy: pathophysiology and advances in treatment.Nature reviews. Endocrinology · 2011Review
- New and emerging agents in the management of lipodystrophy in HIV-infected patients.HIV/AIDS (Auckland, N.Z.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
Abstract
objectiveTo determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue.
methodsIndividual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Generalized estimating equation (GEE) models were used to estimate the treatment effect on changes in limb fat mass.
resultsIn the combined dataset of 427 patients, the baseline median age was 45 years, 86% were male, 80% were Caucasian, 63% were receiving stavudine (d4T) or zidovudine (AZT), 66% were on protease inhibitors, and median body mass index was 23 kg/m(2). In a univariate GEE model, TZD was associated with an increase in limb fat mass (coeff = 0.14 kg vs placebo, P = .04). In a multivariable GEE model, patients receiving pioglitazone had significantly higher limb fat mass gains (coeff = 0.35 kg, P < or = .01) compared to patients receiving placebo, while patients on rosiglitazone did not (coeff = 0.05 kg, P = .48). Interactions between thymidine analogue use and rosiglitazone and pioglitazone were not significant.
conclusionsIn this meta-analysis, pioglitazone therapy was more effective than placebo to increase limb fat mass whereas rosiglitazone was not significantly better than placebo. The effectiveness of these drugs did not vary according to whether the patients were receiving thymidine analogues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.